In recent years, cancer immunotherapy has made remarkable achievements. Immune
checkpoint inhibitors (ICIs) have been used successfully in several types of cancer in the …

Background The relationship between baseline C-reactive protein (CRP) level and the
prognosis of cancer patients receiving immune checkpoint inhibitor (ICI) treatment remains …

Background This clinical trial evaluated a novel telomerase-targeting therapeutic cancer
vaccine, UV1, in combination with ipilimumab, in patients with metastatic melanoma …

Melanoma is a cancer of the pigment-producing cells of the body and its incidence is rising.
Targeted inhibitors that act against kinases in the MAPK pathway are approved for BRAF …

Simple Summary Immune checkpoint inhibitors are increasingly being used in the treatment
of a variety of cancers, both alone and in combination with other cancer therapies. Side …

In recent years cancer treatment has been revolutionized by the development and wide
application of checkpoint inhibitor (CPI) drugs, which are a form of immunotherapy. CPI …

Simple Summary Malignant melanoma is an aggressive cancer with a globally increasing
disease rate. Historically, overall survival has been less than one year for advanced disease …

Background: Immune checkpoint inhibitors (ICIs), including anti-PD-1, anti-PD-L1 and anti-
CTLA-4 antibodies, have become a standard treatment for multiple cancer types. However …

Introduction Cancer cachexia is a clinical condition characterized by recognizable “sickness
behaviors” accompanied by loss of lean body tissue. The Global Leadership on Malnutrition …

The incidence of melanoma is increasing year by year and is highly malignant, with a poor
prognosis. Its treatment has always attracted much attention. Among the more clinically …